ArticlePloS one2025
Construction and validation of a prognostic model based on mitochondria-associated endoplasmic reticulum membranes gene signature in LUAD patients.
Article in PloS one, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- The CCT6A paradigm: biomarker potential and therapeutic challenges in oncology and beyond.Molecular biology reports · 2026Review
- Targeting the Endoplasmic Reticulum Oxidoreductin-1 Alpha-Protein Disulfide Isomerase Redox Interface as a Therapeutic Strategy in Cancer.Biomedicines · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMitochondrial-associated endoplasmic reticulum membranes (MAM) are implicated in various malignancies, but their prognostic value in lung adenocarcinoma (LUAD) remains underexplored.
methodsThe Cancer Genome Atlas (TCGA) and GeneCards databases provided LUAD patient data and MAM-related genes. Differentially expressed genes (DEGs) were identified using the "Limma" package. Enrichment analyses included Gene Ontology (GO), Kyoto Encyclopedia of Genes and Genomes (KEGG), Gene Set Variation Analysis (GSVA), and Gene Set Enrichment Analysis (GSEA). A prognostic risk model based on MAM genes was constructed using univariate, least absolute shrinkage and selection operator (LASSO), and multivariate Cox regression analyses, validated by Receiver Operating Characteristic (ROC) curve analysis. PPI explored intergene relationships, while immune infiltration analysis investigated underlying mechanisms. The Human Protein Atlas (HPA) validated key gene protein expression, and drug sensitivity was analyzed using the Gene Set Cancer Analysis (GSCA) database. Finally, we also performed immunohistochemistry (IHC) staining in the tissue samples.
resultsA prognostic risk model with 3 MAM genes (ERO1A, SHC1, CCT6A) was established from 194 DEGs-MAM. Kaplan-Meier analysis showed significantly longer OS in the low-risk group. Enrichment analyses indicated MAM genes were primarily involved in immune-related pathways. TIMER analysis linked the 3 MAM genes with immune cell infiltration (CD8 + T cells, CD4 + T cells, B cells, macrophages). Expression and prognostic analyses revealed high expression of these mRNAs and proteins in LUAD tissues.
conclusionsThis study constructed a prognostic risk model for LUAD based on 3 MAM genes, revealing a potential link between MAM genes and LUAD, offering new insights into clinical treatment and prognosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.